3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Oropharyngeal Neoplasms
2
Lung Neoplasms
2
Anus Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Mouth Neoplasms
1
Mesothelioma
1
Lymphoma, Mantle-Cell
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
HIV Infections
1
Disease
1
Chordoma
1
Cholangiocarcinoma
1
Carcinoma, Squamous Cell
1
Interventions
X-Rays
4
Phantoms, Imaging
4
Nuclear Medicine Department, Hospital
4
Magnetic Resonance Spectroscopy
4
Specimen Handling
3
Biopsy
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
tazemetostat
1
talazoparib
1
palbociclib
1
olaparib
1
larotrectinib
1
irinotecan sucrosofate
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
Liquid Biopsy
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
Fluorodeoxyglucose F18
×
30 days
×
Clear all
No trials found.